|
| |
RepligenRepligen Corporation is a biotechnology company focused on developing new drugs for debilitating pediatric disorders including autism, immune and metabolic disorders. Repligen has exclusive worldwide rights to market SecreFlo™, which was recently approved by the FDA for pancreatic assessment and manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies.
| Contact Details: |
| 41 Seyon Street Building #1 Suite 100 |
| Waltham |
| MA |
| 02453 |
| United States of America |
| Tel: | (781) 250-0111 |
| Fax: | (781) 250-0115 |
| Email: | info@repligen.com |
| WWW: | www.repligen.com/
|
|
Loading...
|
Recent Publications by Repligen: |  |
A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
PURPOSE: Fumagillin and related compounds have potent antiproliferative... | 31st October, 2006
| Department of Cell Biology, Repligen, Waltham, Massachusetts, USA.
| Clin Cancer Res. 2006 Apr 15;12(8):2583-90.
DOI Direct Link |
Age-related and regional differences in secretin and secretin receptor mRNA levels in the rat brain.
In the present study expression levels of secretin and secretin receptor... | 26th August, 2004
| Repligen Corporation, 41 Seyon Street, Waltham, MA 02453, USA.
| Neurosci Lett. 2004 Aug 12;366(2):176-81.
DOI Direct Link |
A secretin i.v. infusion activates gene expression in the central amygdala of rats.
For the last 100 years secretin has been extensively studied for its... | 12th July, 2003
| Repligen Corporation, Building 1, Suite 100, 41 Seyon Street, Waltham, MA
| Neuroscience. 2003;118(4):881-8.
|
Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis.
Oral administration of the novel anti-inflammatory peptide RDP58 markedly... | 13th December, 2002
| Department of Immunology, The Scripps Research Institute, La Jolla,
| Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii19-24.
|
Unique Structures Generated by Ugi 3CC Reactions Using Bifunctional Starting Materials Containing Aldehyde and Carboxylic Acid.
Oral administration of the novel anti-inflammatory peptide RDP58 markedly... | 25th October, 2001
| RepliGen Corporation, 117 Fourth Avenue, Needham, Massachusetts 02494.
| J Org Chem. 1999 Feb 5;64(3):1074-1076.
|
→View more Repligen research publications. |
Press Releases on Repligen:
|
 |
| Repligen Reports Second Quarter Fiscal Year 2010 Financial Results |
5th November, 2009 |
Repligen Corporation |
WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the
|
| Repligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST |
3rd November, 2009 |
Repligen Corporation |
WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at
|
| Repligen Announces Conference Call of Second Quarter Fiscal Year 2010 Results |
29th October, 2009 |
Repligen Corporation |
WALTHAM, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a
|
| Families of Spinal Muscular Atrophy Licenses Potential Treatment for SMA to Repligen Corporation |
22nd October, 2009 |
Families of Spinal Muscular Atrophy |
ELK GROVE VILLAGE, Ill., Oct. 22 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy (FSMA) announced today that it has entered into a groundbreaking exclusive license agreement with
|
| Repligen Licenses Potential Treatment for Spinal Muscular Atrophy |
22nd October, 2009 |
Repligen Corporation |
WALTHAM, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has entered into an exclusive license agreement with Families of Spinal Muscular Atrophy
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 14 individuals from Repligen using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 374 times since April 2007, the link to the organisation's website has been followed 54 times Recent Search Terms used to find this page: repligen pharmaceuticals | repligen pharmaceuticals | repligen pharmaceuticals | repligen pharmaceuticals | ppi-2458 and repligen | repligen pharmaceuticals | repligen pharmaceuticals | repligen pharmaceuticals | repligen | Repligen | . Search for more companies in Waltham Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Repligen |
